Neophore
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Ashley Road Floor 3, Altrincham, Chesh...Phone Number
+44 3301289990Website
www.neophore.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Neophore
NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Established in 2017, NeoPhore is headquartered in the United Kingdom.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neophore your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Neophore has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neophore launches new products
Neophore, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Neophore had a recent Job posting/layoffs
Check if Neophore has recently received funding, and reach out quickly before it becomes old news!
Check out if Neophore is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Neophore
Earning: See what the market has to say on Neophore recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Neophore as Masked Content
Find more new buyers
Compare Similar Companies to Neophore
Compare insights from companies similar to Neophore, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neophore
<$5M
1-10
Private
$45.5M
2017
N/A
Company Profile Activity
Activity Insights
Neophore is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neophore is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neophore.
Neophore financials insights
Gather financial insights about Neophore, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$3.8M
Other Financing Round
$2.1M
2024
Series B
$39.5M
Neophore Tech Stack
A closer look at the technologies used by Neophore
Most Recent Scoops
Open Position
Open Position
Open Position
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Funding
Funding
Neophore News & Media
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON, May 22, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol...NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) LONDON, Feb. 1, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology...NeoPhore signs research collaboration with The Institute of Cancer Research, London
LONDON, April 18, 2023 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lord's lab at The Institute of Cancer Research, London. The collaboration will use...NeoPhore completes extension to Series B financing to further advance discovery pipeline
Scientific milestones achieved significantly ahead of schedule CAMBRIDGE, England, Jan. 19, 2023 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m)...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Neophore
Sign Up For FreeTo access detailed company insights
NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Established in 2017, NeoPhore is headquartered in the United Kingdom.... Read More
